No abstract

A large percentage of U.S. students attending high-poverty urban middle schools achieve low levels of science proficiency, posing significant challenges to their success in high school science and to national and local efforts to reform science education. Through its work in Philadelphia schools, the Center for Social Organization of Schools at Johns Hopkins University developed a teacher-support model to address variation in science curricula, lack of materials, and underprepared teachers that combined with initial low levels of proficiency block improvements in science achievement. The model includes a common science curriculum based on NSF-supported materials commercially available, ongoing teacher professional development built around day-to-day lessons, and regular inclass support of teachers by expert peer coaches. One cohort of students at three Philadelphia middle schools using the model was followed from the end of fourth grade through seventh grade. Their gains in science achievement and achievement levels were substantially greater than students at 3 matched control schools and the 23 district middle schools serving a similar student population. Under school-by-school comparisons, these results held for the two schools with adequate implementation. Using widely available materials and techniques, the model can be adopted and modified by school partners and districts.

This review of the US Orphan Drug Act (ODA) 1983 outlines how the ODA is intended to stimulate orphan drug research and development of drugs for rare diseases. We also evaluate the effectiveness of the ODA in the past decade and provide recommendations for ODA improvements in the future. The economic incentives embedded in the ODA are presented in a simple economic model, in which a guarantee of market exclusivity plays a central role in encouraging firms to pursue the development of orphan products. Some evidence suggests that this provision has been a major impetus for the rise in orphan drug applications and designations in the last decade. Market exclusivity is the key incentive for orphan drug research, and should be retained. Concerns about a limited number of highly successful 'blockbuster' orphan drugs should be evaluated in terms of the useful economic incentives. In the future, exceptionally high profits could be limited by more precise evaluation of disease prevalence, elasticity of demand, and the other uses of orphan compounds. We further recommend an expansion of the ODA tax credits and research grants programme and targeting of 'priority' diseases. We conclude that the ODA has been a valuable legislative initiative, but it can be strengthened with some simple extensions of the current incentives that it contains.

No abstract

No abstract